Ibnsina Pharma (ISPH)
Egyptian Exchange · Egypt · prices in EGP · close of 22 Oct 2026
Key indicators
| Last close | EGP 10.07 |
|---|---|
| 52-week range | 9.63 – 16.93 |
| Return, 1 month / 3 months | −17.5% / −13.2% |
| Return, 1 year / 3 years | −7.6% / +397.6% |
| Trend | Below its 200-day average |
| RSI (14) | 25 |
| Volatility (1 year) | 39.3% |
| Worst drawdown (1 year) | -30.0% |
| Average daily value traded | 111.26M EGP |
| Dividend yield | 2.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Ibnsina Pharma is a pharmaceutical distribution company based in Egypt. It buys medicines and healthcare products from drug makers and supplies them to pharmacies, hospitals and other healthcare outlets across the country. The company runs warehousing and delivery operations that move these products through its distribution network, serving both independent and chain pharmacies as well as medical institutions. Its business centres on making prescription and over-the-counter medicines reliably available to healthcare providers throughout Egypt.
On this site Ibnsina Pharma appears as a stock on the Egyptian Exchange (Egypt), code ISPH, with prices in Egyptian pounds (EGP). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Ibnsina Pharma (ISPH) trades on the Egyptian Exchange in Egypt. It last closed at EGP 10.07 on 22 October 2026.
Its price-based Market X-Ray is 47 out of 100 (a weak price profile), ranking 164 of 276 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 7.6% and over the last three months it fell 13.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Egyptian Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 32 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -12.4% | ||
| From 52-week high | -30.8% | ||
| Momentum | 29 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -13.2% | ||
| 6-month return | -7.0% | ||
| 12-month return, skipping the last month | 12.0% | ||
| Stability (higher is calmer) | 60 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 39.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -30.0% | ||
| Liquidity | 89 · Strong | Trades actively. | |
| Average daily value traded | 111.26M EGP | ||
| Zero-volume days | 0.0% | ||
| Income | 31 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.6% | ||
| Years with dividends | 3 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | −10.6% |
|---|---|
| 1 month | −17.5% |
| 3 months | −13.2% |
| 6 months | −7.0% |
| 1 year | −7.6% |
| 3 years | +397.6% |
| 5 years | +301.8% |
Signals
| 50-day / 200-day average | 12.17 / 11.49 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.44 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 12 Oct 2026 | EGP 0.1300 |
| 27 Apr 2026 | EGP 0.1300 |
| 13 Oct 2025 | EGP 0.1600 |
| 6 Jun 2022 | EGP 0.1003 |
| 22 Apr 2020 | EGP 0.0700 |
| 15 May 2019 | EGP 0.0705 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Egyptian Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.